Dr. Fred T. Fiedorek is the chief medical officer (CMO) at Verve Therapeutics. He has more than 20 years of experience in clinical development and leadership, primarily in therapeutic areas such as diabetes, cardiovascular disease and endocrine/metabolic diseases. Prior to Verve, Fred held CMO roles at Rhythm Pharmaceuticals, Intarcia Therapeutics and a stealth company within Atlas Venture. In addition, he served as a senior advisor to Foresite Capital Management. Prior to these roles, he spent 13 years at Bristol-Myers Squibb (BMS), where he was most recently senior vice president, head of cardiovascular and metabolic development responsible for leading Phase 2 through Phase 4 global development for the cardiovascular and metabolic therapeutic areas. Under his leadership, several new medicines achieved successful marketing authorization, including Eliquis® (apixaban), Farxiga® (dapagliflozin), Onglyza® (saxagliptin) and Myalept® (metreleptin). Prior to BMS, Fred was international project leader for metabolic drug development at Glaxo-Wellcome.
Fred received an M.D. from Harvard Medical School and trained in internal medicine and endocrinology and metabolism at Washington University School of Medicine in St. Louis. He also served on the faculty at the University of North Carolina School of Medicine.